2024 ICD-10-CM Diagnosis Code C69.20

Malignant neoplasm of unspecified retina

ICD-10-CM Code:
C69.20
ICD-10 Code for:
Malignant neoplasm of unspecified retina
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:

Code Classification

  • Neoplasms
    (C00–D49)
    • Malignant neoplasms of eye, brain and other parts of central nervous system
      (C69-C72)
      • Malignant neoplasm of eye and adnexa
        (C69)

C69.20 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of unspecified retina. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

The following anatomical sites found in the Table of Neoplasms reference the parent code C69.2 of the current diagnosis code given the correct histological behavior: Neoplasm, neoplastic retina .

Unspecified diagnosis codes like C69.20 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Malignant tumor of retina
  • Melanoma-associated retinopathy
  • Paraneoplastic retinopathy
  • Primary adenocarcinoma of iris neuroepithelium
  • Primary malignant neoplasm of retina
  • Primary malignant neuroepithelial neoplasm of retina
  • Primary retinal pigment epithelial adenocarcinoma
  • Retinal pigment epithelial adenocarcinoma
  • Retinoblastoma

Clinical Classification

Clinical Information

  • E2F1 Transcription Factor

    an e2f transcription factor that interacts directly with retinoblastoma protein and cyclin a and activates genetic transcription required for cell cycle entry and dna synthesis. e2f1 is involved in dna repair and apoptosis.
  • Genes, Retinoblastoma

    tumor suppressor genes located on human chromosome 13 in the region 13q14 and coding for a family of phosphoproteins with molecular weights ranging from 104 kda to 115 kda. one copy of the wild-type rb gene is necessary for normal retinal development. loss or inactivation of both alleles at this locus results in retinoblastoma.
  • Retinoblastoma

    a malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. the tumor tends to occur in early childhood or infancy and may be present at birth. the majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. an abnormal pupil reflex (leukokoria); nystagmus, pathologic; strabismus; and visual loss represent common clinical characteristics of this condition. (from devita et al., cancer: principles and practice of oncology, 5th ed, p2104)
  • Retinoblastoma Binding Proteins

    a family of endogenous regulatory proteins that associate with retinoblastoma protein via a specific high-affinity binding domain. members of this family of proteins are often found associated with histone-modifying enzymes and protein complexes that regulate gene expression.
  • Retinoblastoma Protein

    product of the retinoblastoma tumor suppressor gene. it is a nuclear phosphoprotein hypothesized to normally act as an inhibitor of cell proliferation. rb protein is absent in retinoblastoma cell lines. it also has been shown to form complexes with the adenovirus e1a protein, the sv40 t antigen, and the human papilloma virus e7 protein.
  • Retinoblastoma-Binding Protein 1

    a ubiquitously expressed regulatory protein that contains a retinoblastoma protein binding domain and an at-rich interactive domain. the protein may play a role in recruiting histone deacetylases to the site of retinoblastoma protein-containing transcriptional repressor complexes.
  • Retinoblastoma-Binding Protein 2

    a retinoblastoma binding protein that is also a member of the jumonji-domain histone demethylases. it has demethylation activity towards specific lysine residues found on histone h3.
  • Retinoblastoma-Binding Protein 4

    a retinoblastoma-binding protein that is involved in chromatin remodeling, histone deacetylation, and repression of genetic transcription. although initially discovered as a retinoblastoma binding protein it has an affinity for core histones and is a subunit of chromatin assembly factor-1 and polycomb repressive complex 2.
  • Retinoblastoma-Binding Protein 7

    a retinoblastoma-binding protein that has an affinity for core histones. it is found as a subunit of protein complexes that are in involved in the enzymatic modification of histones including the mi2 and sin3 histone deacetylase complexes and the polycomb repressive complex 2.
  • Retinoblastoma-Like Protein p107

    a negative regulator of the cell cycle that undergoes phosphorylation by cyclin-dependent kinases. it contains a conserved pocket region that binds e2f4 transcription factor and interacts with viral oncoproteins such as polyomavirus tumor antigens; adenovirus e1a proteins; and papillomavirus e7 proteins.
  • Retinoblastoma-Like Protein p130

    a negative regulator of the cell cycle that undergoes phosphorylation by cyclin-dependent kinases. rbl2 contains a conserved pocket region that binds e2f4 transcription factor and e2f5 transcription factor. rbl2 also interacts with viral oncoproteins such as polyomavirus tumor antigens; adenovirus e1a proteins; and papillomavirus e7 proteins.
  • Histones

    small chromosomal proteins (approx 12-20 kd) possessing an open, unfolded structure and attached to the dna in cell nuclei by ionic linkages. classification into the various types (designated histone i, histone ii, etc.) is based on the relative amounts of arginine and lysine in each.

Convert C69.20 to ICD-9-CM

  • ICD-9-CM Code: 190.5 - Malign neopl retina
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Neoplasms

The parent code C69.2 of the current diagnosis code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»Neoplasm, neoplastic
  »retina
C69.2C79.49D09.2D31.2D48.7D49.81

Patient Education


Eye Cancer

Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body.

Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.


[Learn More in MedlinePlus]

Retinoblastoma

Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. This form of cancer develops in the retina, which is the specialized light-sensitive tissue at the back of the eye that detects light and color.

In children with retinoblastoma, the disease often affects only one eye. However, one out of three children with retinoblastoma develops cancer in both eyes. The most common first sign of retinoblastoma is a visible whiteness in the pupil called "cat's eye reflex" or leukocoria. This unusual whiteness is particularly noticeable in dim light or in photographs taken with a flash. Other signs and symptoms of retinoblastoma include crossed eyes or eyes that do not point in the same direction (strabismus), which can cause squinting; a change in the color of the colored part of the eye (iris); redness, soreness, or swelling of the eyelids; and blindness or poor vision in the affected eye or eyes.

Retinoblastoma is often curable when it is diagnosed early. However, if it is not treated promptly, this cancer can spread beyond the eye to other parts of the body. This advanced form of retinoblastoma can be life-threatening.

When retinoblastoma is associated with a genetic change (mutation) that occurs in all of the body's cells, it is known as hereditary (or germinal) retinoblastoma. People with this form of retinoblastoma typically develop cancer in both eyes and also have an increased risk of developing several other cancers outside the eye. Specifically, they are more likely to develop a cancer of the pineal gland in the brain (pineoblastoma), a type of bone cancer known as osteosarcoma, cancers of soft tissues (such as muscle) called soft tissue sarcomas, and an aggressive form of skin cancer called melanoma.


[Learn More in MedlinePlus]

Retinoblastoma Treatment (PDQ®)

Learn about retinoblastoma risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.